CA3234615A1 - Modified proteins and protein degraders - Google Patents
Modified proteins and protein degraders Download PDFInfo
- Publication number
- CA3234615A1 CA3234615A1 CA3234615A CA3234615A CA3234615A1 CA 3234615 A1 CA3234615 A1 CA 3234615A1 CA 3234615 A CA3234615 A CA 3234615A CA 3234615 A CA3234615 A CA 3234615A CA 3234615 A1 CA3234615 A1 CA 3234615A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/123848 | 2021-10-14 | ||
| CN2021123848 | 2021-10-14 | ||
| CNPCT/CN2021/133363 | 2021-11-26 | ||
| CN2021133363 | 2021-11-26 | ||
| PCT/CN2022/125080 WO2023061440A1 (en) | 2021-10-14 | 2022-10-13 | Modified proteins and protein degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234615A1 true CA3234615A1 (en) | 2023-04-20 |
Family
ID=85987275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234615A Pending CA3234615A1 (en) | 2021-10-14 | 2022-10-13 | Modified proteins and protein degraders |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235543A1 (https=) |
| EP (1) | EP4416145A1 (https=) |
| JP (1) | JP2024537394A (https=) |
| CN (1) | CN118451078A (https=) |
| AU (1) | AU2022362494A1 (https=) |
| CA (1) | CA3234615A1 (https=) |
| IL (1) | IL312013A (https=) |
| MX (1) | MX2024004525A (https=) |
| WO (1) | WO2023061440A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US20260092062A1 (en) * | 2022-09-26 | 2026-04-02 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| CN121005703A (zh) * | 2024-05-24 | 2025-11-25 | 中国科学院广州生物医药与健康研究院 | 一种酰胺吲嗪类化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445765A4 (en) * | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| EP3807272A1 (en) * | 2018-06-13 | 2021-04-21 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| US20220002291A1 (en) * | 2018-11-02 | 2022-01-06 | The Wistar Institute Of Anatomy And Biology | Proteolysis-targeting chimeras |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| WO2020206608A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| WO2020219650A1 (en) * | 2019-04-23 | 2020-10-29 | Dana-Farber Cancer Institute, Inc. | Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof |
| CN112409376A (zh) * | 2019-08-20 | 2021-02-26 | 华东师范大学 | 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用 |
| CN120623106A (zh) * | 2019-09-30 | 2025-09-12 | 协和麒麟株式会社 | Bet降解剂 |
| WO2021239117A1 (en) * | 2020-05-28 | 2021-12-02 | Cullgen (Shanghai) , Inc. | Modified proteins and protein degraders |
-
2022
- 2022-10-13 IL IL312013A patent/IL312013A/en unknown
- 2022-10-13 WO PCT/CN2022/125080 patent/WO2023061440A1/en not_active Ceased
- 2022-10-13 CN CN202280082680.9A patent/CN118451078A/zh active Pending
- 2022-10-13 JP JP2024522487A patent/JP2024537394A/ja active Pending
- 2022-10-13 US US18/700,898 patent/US20250235543A1/en active Pending
- 2022-10-13 MX MX2024004525A patent/MX2024004525A/es unknown
- 2022-10-13 CA CA3234615A patent/CA3234615A1/en active Pending
- 2022-10-13 AU AU2022362494A patent/AU2022362494A1/en active Pending
- 2022-10-13 EP EP22880376.3A patent/EP4416145A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024537394A (ja) | 2024-10-10 |
| US20250235543A1 (en) | 2025-07-24 |
| EP4416145A1 (en) | 2024-08-21 |
| IL312013A (en) | 2024-06-01 |
| AU2022362494A1 (en) | 2024-05-23 |
| CN118451078A (zh) | 2024-08-06 |
| WO2023061440A1 (en) | 2023-04-20 |
| MX2024004525A (es) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3011855T3 (en) | Tyk2 inhibitors and uses thereof | |
| AU2021201536A1 (en) | Inhibitors of cyclin-dependent kinase 7 (CDK7) | |
| CA3234615A1 (en) | Modified proteins and protein degraders | |
| CA2927917C (en) | Heteroaromatic compounds useful for the treatment of proliferative diseases | |
| ES2948782T3 (es) | Inhibidores de la desmetilasa 1 específica de lisina | |
| CN106660987B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| US9556171B2 (en) | Certain protein kinase inhibitors | |
| CA2882733A1 (en) | Novel 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents | |
| CA2927920A1 (en) | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| AU2006283592A1 (en) | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators | |
| WO2008109154A1 (en) | Chemokine receptor modulators | |
| CA2954060A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| CA3171187A1 (en) | Inhibitors of ulk1/2 and methods of using same | |
| JP2020143161A (ja) | ＣａＭＫＩＩ阻害剤及びその使用 | |
| WO2023283364A2 (en) | N,n-dimethyltryptamine and related psychedlics and uses thereof | |
| JP5558470B2 (ja) | エピポドフィロトキシンの新規な（ポリ）アミノアルキルアミノアルキルアミド、アルキル−尿素またはアルキル−スルホンアミド誘導体、それらの製造方法、および治療における抗癌剤としてのそれらの応用 | |
| WO2016203335A1 (en) | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors | |
| US20190337902A1 (en) | Heterocyclic compounds as hiv protease inhibitors | |
| KR20230170684A (ko) | Lrrk2 키나제 억제제로서 유용한 피리미딘 유도체 | |
| TWI297338B (en) | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | |
| ES2470291T3 (es) | Compuestos de bis-arilamida y métodos de uso | |
| CN106660971A (zh) | 用于神经退行性疾病和阿尔茨海默病的治疗中的用途的双重抑制剂化合物 | |
| HK40105557B (zh) | Tyk2抑制剂及其用途 | |
| HK40105557A (zh) | Tyk2抑制剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240923 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241004 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241004 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251003 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251003 |